Today: 20 May 2026
Nestle stock faces Monday test after France probes baby deaths tied to recalled formula
25 January 2026
1 min read

Nestle stock faces Monday test after France probes baby deaths tied to recalled formula

Zurich, Jan 25, 2026, 19:58 CET — Market closed.

  • On Friday, Nestle shares ended the session down 1.0%, closing at 72.47 Swiss francs.
  • France is investigating two infant deaths linked to formula that had been subject to precautionary recalls.
  • Traders await investigative findings due in the coming days, along with Nestle’s results on Feb. 19.

Nestle shares face pressure as Swiss markets open Monday, following French authorities launching investigations into the deaths of two infants linked to baby formula from precautionary recalls.

The Swiss food group’s shares ended the session down 0.98%, closing at 72.47 Swiss francs. This price point could expose the stock to fresh headline-driven swings once trading restarts.

This is critical now since infant nutrition hinges on trust, and the incident keeps Nestle under scrutiny while it struggles to contain an expanding formula recall. The longer the problem drags on, the more investors prepare for higher expenses, sales declines, or increased regulatory pressure.

This also comes before Nestle’s next big event: the full-year results set for Feb. 19.

French investigators are looking into whether the deaths are connected to the products, but the health ministry says no causal link has been found yet. The recalls involve potential contamination with cereulide, a toxin known to cause nausea and vomiting.

Nestle rejected any connection between its products and the deaths, stating in an email: “at this stage nothing indicates any link between these tragic events and the consumption of our products.” Reuters

On Friday, shares moved within a tight band from 71.96 to 73.07 francs but closed down, market data show. This limited fluctuation hints that investors haven’t sharply adjusted their risk outlook — at least not so far.

The problem isn’t limited to Nestle. Lactalis has pulled infant milk from shelves in several countries, while Danone has flagged concerns over a batch destined for Singapore. This points to a wider supply-chain issue in the sector.

Traders will be closely monitoring any updates from prosecutors and ministries in the week ahead, looking for clues on whether the recall perimeter will expand or hold steady. France’s farm ministry said it expects results from an initial judicial inquiry within the next 10 days.

Macro factors remain in play. On Monday, Switzerland’s central bank will release “important monetary policy data,” a report likely to influence the franc and shape rate expectations crucial to global giants such as Nestle. Swiss National Bank Data Portal

The path is straightforward. Should investigators come up empty and the recall fade, the stock might shift back to focusing on rates and earnings forecasts. But if a connection is proven, legal risks and reputational harm could escalate quickly, prompting investors to factor in a prolonged drop in volumes.

Next on the docket: official findings from France expected within the 10-day timeframe, followed by Nestle’s February 19 earnings release. Management will need to address the financial fallout and confirm if the disruption is under control.

Stock Market Today

  • Roper Technologies (ROP) Trading Below Analyst Targets, Potentially Undervalued
    May 19, 2026, 11:35 PM EDT. Roper Technologies (ROP) shares fell about 9% in the past month to $328.91, with a 1-year total shareholder return down 42.68%, reflecting investor concerns over growth and risk balance. Analysts estimate a fair value around $453.75, implying the stock is 27.5% undervalued. This view hinges on Roper's continued growth via acquisitions and AI-driven software, supporting strong cash flow and EBITDA margin expansion. However, risks include potential integration challenges and rising competition. Investors are advised to carefully assess Roper's revenue trajectory, profit margins, and execution capabilities amid mixed market sentiment.

Latest articles

Wall Street Hit by Yield Jolt With Nvidia Up Next

Wall Street Hit by Yield Jolt With Nvidia Up Next

20 May 2026
U.S. stock ETFs remained lower late Tuesday after Wall Street’s main indexes fell for a third straight session, pressured by rising Treasury yields and caution ahead of Nvidia’s earnings. The SPDR S&P 500 ETF dropped 0.7% to $733.73. The 10-year Treasury yield hit 4.687%, its highest since January 2025, before easing. Nvidia shares slipped 0.7% after hours, with traders bracing for a major move post-earnings.
Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

Viavi Stock Drops After $500 Million Share Sale Plan — The Debt Move Investors Can’t Ignore

20 May 2026
Viavi Solutions shares dropped 7.1% in after-hours trading Tuesday after the company announced a $500 million public stock offering aimed at repaying debt. The offering, unveiled just after the Nasdaq close, could add roughly 10.1 million new shares. Viavi plans to use proceeds to pay down a $450 million loan. Total debt would fall to $650 million, according to a preliminary SEC filing.
Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

Analog Devices Shares Rally After $1.5B AI Power Deal Ahead of Earnings

20 May 2026
Analog Devices agreed to acquire Empower Semiconductor for $1.5 billion in cash, sending ADI shares up 1.36% to $419.95 in after-hours trading after closing down 1.02%. The deal, approved by both boards, is expected to close in the second half of 2026 pending regulatory review. Empower CEO Tim Phillips will continue to lead integrated voltage regulator work after the merger.
Micron stock hovers near $400 as Intel flags memory cost pressure; Fed decision next
Previous Story

Micron stock hovers near $400 as Intel flags memory cost pressure; Fed decision next

NextEra Energy stock price: NEE set for earnings-week test after insider sale filing
Next Story

NextEra Energy stock price: NEE set for earnings-week test after insider sale filing

Go toTop